ESMO Asia 2025 – Oric’s first-line gamble
Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ADC slides on latest Zynlonta update
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
Black Diamond picks brain cancer for silevertinib
Though lung cancer looks promising a partner is now needed.
Imvax’s brain fail
But the group still hopes to get IGV-001 approved based on overall survival data.
Janux lets the genie out of the bottle
A more comprehensive dataset on JANX007 sends the group’s stock down.
BioNTech’s big gotistobart day approaches
Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.
ASH 2025 preview – toxicity worries hit BeOne’s sonrotoclax
The project has priority review, but deaths could raise eyebrows.
ASH 2025 preview – Kelonia gets a late-breaking coup
An in vivo Car-T produced a 100% response rate – in three patients.
